Form 4: UNITED THERAPEUTICS CEO Sells Shares
Insider Transaction (Form 4)
Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on July 17, 2026.
Summary
- Option exercise/conversion: acquired 9,500 Common Stock at $135.42 ($1,286,490) on July 17, 2026; holds 333,943 after (Indirect).
- Open-market sale: disposed of 240 Common Stock at $528.91 ($126,938) on July 17, 2026; holds 333,703 after (Indirect).
- Open-market sale: disposed of 240 Common Stock at $530.83 ($127,400) on July 17, 2026; holds 333,463 after (Indirect).
- Open-market sale: disposed of 720 Common Stock at $534.57 ($384,889) on July 17, 2026; holds 332,743 after (Indirect).
- Open-market sale: disposed of 2,350 Common Stock at $535.53 ($1,258,486) on July 17, 2026; holds 330,393 after (Indirect).
- Open-market sale: disposed of 2,110 Common Stock at $536.36 ($1,131,717) on July 17, 2026; holds 328,283 after (Indirect).
- Open-market sale: disposed of 1,160 Common Stock at $537.45 ($623,438) on July 17, 2026; holds 327,123 after (Indirect).
- Open-market sale: disposed of 423 Common Stock at $538.70 ($227,871) on July 17, 2026; holds 326,700 after (Indirect).
- Open-market sale: disposed of 821 Common Stock at $539.63 ($443,033) on July 17, 2026; holds 325,879 after (Indirect).
- Open-market sale: disposed of 251 Common Stock at $540.69 ($135,714) on July 17, 2026; holds 325,628 after (Indirect).
- Open-market sale: disposed of 892 Common Stock at $542.06 ($483,521) on July 17, 2026; holds 324,736 after (Indirect).
- Open-market sale: disposed of 293 Common Stock at $542.43 ($158,932) on July 17, 2026; holds 324,443 after (Indirect).
- Option exercise/conversion: disposed of 9,500 Stock Option on July 17, 2026; holds 322,410 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $5,101,939 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Martine A Rothblatt — Director, Officer (Chairperson & CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-17 | Option exercise/conversion | Common Stock | 9,500 | $135 | $1.3M | 333,943 |
| 2026-07-17 | Open-market sale | Common Stock | 240 | $529 | $126.9K | 333,703 |
| 2026-07-17 | Open-market sale | Common Stock | 240 | $531 | $127.4K | 333,463 |
| 2026-07-17 | Open-market sale | Common Stock | 720 | $535 | $384.9K | 332,743 |
| 2026-07-17 | Open-market sale | Common Stock | 2,350 | $536 | $1.3M | 330,393 |
| 2026-07-17 | Open-market sale | Common Stock | 2,110 | $536 | $1.1M | 328,283 |
| 2026-07-17 | Open-market sale | Common Stock | 1,160 | $537 | $623.4K | 327,123 |
| 2026-07-17 | Open-market sale | Common Stock | 423 | $539 | $227.9K | 326,700 |
| 2026-07-17 | Open-market sale | Common Stock | 821 | $540 | $443.0K | 325,879 |
| 2026-07-17 | Open-market sale | Common Stock | 251 | $541 | $135.7K | 325,628 |
| 2026-07-17 | Open-market sale | Common Stock | 892 | $542 | $483.5K | 324,736 |
| 2026-07-17 | Open-market sale | Common Stock | 293 | $542 | $158.9K | 324,443 |
| 2026-07-17 | Option exercise/conversion | Stock Option | 9,500 | — | — | 322,410 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-17 | Option exercise/conversion (9,500 shares) |
| 2026-07-17 | Open-market sale (240 shares) |
| 2026-07-17 | Open-market sale (240 shares) |
| 2026-07-17 | Open-market sale (720 shares) |
| 2026-07-17 | Open-market sale (2,350 shares) |
| 2026-07-17 | Open-market sale (2,110 shares) |
| 2026-07-17 | Open-market sale (1,160 shares) |
| 2026-07-17 | Open-market sale (423 shares) |
| 2026-07-17 | Open-market sale (821 shares) |
| 2026-07-17 | Open-market sale (251 shares) |
| 2026-07-17 | Open-market sale (892 shares) |
| 2026-07-17 | Open-market sale (293 shares) |
| 2026-07-17 | Option exercise/conversion (9,500 shares) |
Keywords
insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.